Literature DB >> 16453193

Switching from dorzolamide to brinzolamide: effect on intraocular pressure and patient comfort.

Kenji Inoue, Shige-aki Wada, Masato Wakakura, Jiro Inoue, Goji Tomita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16453193     DOI： 10.1007/s10384-005-0271-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN： 0021-5155            Impact factor:   2.447


× No keyword cloud information.
  3 in total

1.  The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group.

Authors:  K Sall
Journal:  Surv Ophthalmol       Date:  2000-01       Impact factor: 6.048

2.  Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting.

Authors:  H Barnebey; S Y Kwok
Journal:  Clin Ther       Date:  2000-10       Impact factor: 3.393

3.  Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.

Authors:  L H Silver
Journal:  Am J Ophthalmol       Date:  1998-09       Impact factor: 5.258
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.